The words you are searching are inside this book. To get more targeted content, please make full-text search by clicking here.

Can INDIA Dethrone CHINA In API PRODUCTION?
The past decade has witnessed a steady growth and commitment of the Indian government in addressing issues like ‘self-reliance and self-sufficiency’ in all aspects of governance and decisions. While sops and subsidies were, indeed, crucial to many concerns of industries and stakeholders, key decisions and schemes were lacking, until numerous ‘Aatmanirbhar Projects’ were kicked off by the Centre. One such crucial initiative addresses the need for Bulk Drugs Parks in India, making the country less dependent on Chinese Active Pharmaceutical Ingredients (APIs), providing more employment and generating more revenue that will add to the country’s GDP. A laudable step has been taken with the launching of three Bulk Drugs projects across three states in the country, with an estimated time of completion set at 5 years. We shall take a closer look at what the project entails and seek expert views from a few industry stalwarts.

Discover the best professional documents and content resources in AnyFlip Document Base.
Search
Published by MMA Media, 2022-11-29 02:57:35

BioSpectrum India 2022

Can INDIA Dethrone CHINA In API PRODUCTION?
The past decade has witnessed a steady growth and commitment of the Indian government in addressing issues like ‘self-reliance and self-sufficiency’ in all aspects of governance and decisions. While sops and subsidies were, indeed, crucial to many concerns of industries and stakeholders, key decisions and schemes were lacking, until numerous ‘Aatmanirbhar Projects’ were kicked off by the Centre. One such crucial initiative addresses the need for Bulk Drugs Parks in India, making the country less dependent on Chinese Active Pharmaceutical Ingredients (APIs), providing more employment and generating more revenue that will add to the country’s GDP. A laudable step has been taken with the launching of three Bulk Drugs projects across three states in the country, with an estimated time of completion set at 5 years. We shall take a closer look at what the project entails and seek expert views from a few industry stalwarts.

Keywords: API PRODUCTION,Pharma industry

"We Communicate
directly with
Life-Science
Leaders and
BioPharma
Executives
World-Wide"

www.biospectrumasia.com www.biospectrumindia.com

For More information , Please contact [email protected]


RNI TC No. MAHENG14628 RNI NO. DELENG/2004/13061
Date of Publication - 30.11.2022 Date of Posting - 1.12.2022

Research Services

DNA Based #GENOMICSFORALL

• Viral Sequencing Clinical
• Whole Genome Sequencing Genomics

(Bacteria, Fungi, Insects, Human, etc.) • Infectious Diseases
(Tuberculosis, HPV)
RNA Based Epigenetics
• Cancer
• Viral Sequencing • Whole Genome • Whole Exome
• Whole Transcriptome Sequencing Bisulfite Sequencing
• Circular RNA Sequencing Sequencing
• Small RNA Sequencing • MeDIP-Seq • HLA typing
• Long non-coding RNA Sequencing • ChIP-Seq
• RIP-Seq
Metagenomics
Computation
• Shotgun Metagenomics
• Shotgun Metatranscriptomics • Bioinformatics Analysis
• 16S/18S rDNA/rRNA Sequencing • Drug Repurposing
• Fungal ITS Sequencing

WHY • High Sensitivity, Variant calling confidence, Resolution
• High depth and deep coverage
NGS • Multigene testing potential
• High troughput leading to optimum cost
• Range of Genetic Variations possible to detect on a single platform

Multigene High Resolution Upto 4 field Nomenclature HLA Application

HLA
Typing

Exome • Understanding the Coding & UTR regions of your genome through exome analysis.
Analysis • 85% of disease causing variants are found in exomes.
Cancer • Cost effective alternative to WGS.
• Incresed variant discovery potential for population gentics & cancer genetics.
including rare and frequency mutation.
• 35 to 36.5 mb exome reading is possible only through NGS.

• NGS enables precision oncology through precision diagnostics. SOLVING CANCER
• Multiple biomarker testing in cancer for optimal cancer care by maximizing
treatment efficacy and minimizing window period of disease progression. YOU CAN’T CURE WHAT YOU
• Multigene testing on small sample volume. DON’T UNDERSTAND
• High sensitivity testing from liquid biopsy specimens for disease relapse or
monitoring.

www. mibiome.com +91 96502 31515
[email protected] [email protected]

Flexcel Park, C Wing, Jogeshwari West, Mumbai 400102, Maharashtra, India.


Click to View FlipBook Version